Biosimilar trastuzumab: Phase III data

Top-line data from a double-blind, international Phase III trial in 725 patients with HER2-positive early breast cancer showed that ABP 980 plus paclitaxel and surgery was non-inferior

Read the full 271 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE